Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD4205 in Relapsed/Refractory Peripheral T-cell Lymphoma
CTR20192726Phase 2Completed
- Sponsor
- Dizal Pharmaceutical Co., Ltd.
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of golidocitinib in peripheral T-cell lymphoma (PTCL), sponsored by Dizal Pharmaceutical Co., Ltd.. Started Jan 2020; status: completed.
02
Drugs
golidocitinib
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on CTR20192726.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192726.